Catabasis Pharmaceuticals, Inc. (CATB)
Catabasis Pharmaceuticals, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Boston, MA, US. The stock last traded at $8.54, down 6.97% on the session, giving a market capitalisation of $234.9M. On trailing twelve-month figures it carries a trailing P/E of -5.02, a net margin of -13938.2%. Its beta of 1.66 implies it has historically moved more than the broad market.
Catabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic treatments primarily within the United States. Their leading experimental drug, edasalonexent, is an oral small molecule undergoing Phase III clinical trials for Duchenne Muscular Dystrophy (DMD), functioning by inhibiting nuclear factor kappa-light-chain-enhancer of activated B cells. Additionally, the company is developing CAT-5571 as a potential treatment for cystic fibrosis. Catabasis also engages in collaborative research, including a preclinical partnership with the Jain Foundation to investigate edasalonexent for dysferlinopathy, and an agreement with the Bill & Melinda Gates Medical Research Institute to study CAT-5571 for both drug-sensitive and drug-resistant tuberculosis. The company was established in 2008 and is based in Boston, Massachusetts.
Catabasis Pharmaceuticals, Inc. is most often compared with the following Healthcare names: